Claims
- 1. A pharmaceutical composition for the prevention or treatment of Alzheimer's disease, comprising an effective amount of one or more compounds which are biliary acid reuptake inhibitors (BARI), and one or more pharmaceutically acceptable carriers, diluents or excipients, or a mixture thereof.
- 2. The composition as set forth in claim 1 wherein the BARI is a compound of formula (IA):
- 3. The composition as set forth in claim 2 wherein the compound is having the following formula:
- 4. The composition as set forth in claim 1 wherein the BARI is a compound of formula (IB):
- 5. The composition as set forth in claim 4 wherein the compound is having the following formula:
- 6. The composition as set forth in claim 1 which is administered orally.
- 7. The composition as set forth in claim 6 which contains from about 0.02 to about 50 mg of the biliary acid reuptake inhibitor.
- 8. The composition as set forth in claim 1 wherein one or more biliary acid reuptake inhibitors are combined with one or more compounds chosen from HMG-CoA reductase inhibitors, cholesterol uptake inhibitors, cholesterol synthesis inhibitors or γ and β APP secretase inhibitors.
- 9. The composition as set forth in claim 8 wherein the various active ingredients are administered simultaneously, separately or spaced out over time.
- 10. A pharmaceutical composition for the prevention or treatment of Alzheimer's disease, comprising an effective amount of one or more compounds which reduce the plasma cholesterol levels without the need to be absorbed in the body after their oral administration, and one or more pharmaceutically acceptable carriers, diluents or excipients, or a mixture thereof.
- 11. The composition as set forth in claim 10 wherein the compound is of the following formula (IA):
- 12. The composition as set forth in claim 11 wherein the compound is having the following formula:
- 13. The composition as set forth in claim 10 wherein the compound is of the following formula (IB):
- 14. The composition as set forth in claim 13 wherein the compound is having the following formula:
- 15. The composition as set forth in claim 10 which is administered orally.
- 16. The composition as set forth in claim 15 which contains from about 0.02 to about 50 mg of the compound.
- 17. The composition as set forth in claim 10 wherein one or more biliary acid reuptake inhibitors are combined with one or more compounds chosen from HMG-CoA reductase inhibitors, cholesterol uptake inhibitors, cholesterol synthesis inhibitors or γ and β APP secretase inhibitors.
- 18. The composition as set forth in claim 17 wherein the various active ingredients are administered simultaneously, separately or spaced out over time.
- 19. A method for the prevention or treatment of Alzheimer's disease in a patient at risk of developing said disease or in the course of developing said disease, comprising administering to said patient an effective amount of a compound having a hypocholesterolemic activity wherein said compound does not penetrate into the body after its oral administration.
- 20. The method as set forth in claim 19 wherein the compound having a hypocholesterolemic activity and not penetrating into the body is a biliary acid reuptake inhibitor.
- 21. The method as set forth in claim 20, wherein the biliary acid reuptake inhibitor is a compound of formula (IA):
- 22. The method as set forth in claim 21 wherein the compound is having the following formula:
- 23. The method as set forth in claim 20 wherein the biliary acid reuptake inhibitor is a compound of formula (IB):
- 24. The method as set forth in claim 23 wherein the compound is having the following formula:
- 25. The method as set forth in claim 19 wherein the compound is administered orally.
- 26. The method as set forth in claim 25 wherein the compound is administered in an amount from about 0.02 mg to about 50 mg.
- 27. The method as set forth in claim 20 wherein one or more biliary acid reuptake inhibitors are administered in combination with one or more compounds chosen from HMG-CoA reductase inhibitors, cholesterol uptake inhibitors, cholesterol synthesis inhibitors or γ and β APP secretase inhibitors.
- 28. The composition as set forth in claim 27 wherein the various active ingredients are administered simultaneously, separately or spaced out over time.
Priority Claims (1)
Number |
Date |
Country |
Kind |
0215722 |
Dec 2002 |
FR |
|
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Application No. 60/455,354, filed Mar. 17, 2003 and the benefit of priority of French Patent Application No. 02/15,722, filed Dec. 12, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60455354 |
Mar 2003 |
US |